Cholesterol sulfate
Star0
Identification
- Generic Name
- Cholesterol sulfate
- DrugBank Accession Number
- DB01990
- Background
Component of human seminal plasma & spermatozoa.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 466.717
Monoisotopic: 466.31168065 - Chemical Formula
- C27H46O4S
- Synonyms
- Cholest-5-en-3beta-ol sulfate
- Cholesterol 3-sulfate
- Cholesterol 3-sulphate
- Cholesterol hydrogen sulfate
- Cholesterol hydrogen sulphate
- Cholesterol sulphate
- Cholesterol-Sulfate
- Cholesteryl sulphate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UNuclear receptor ROR-alpha Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cholesterols and derivatives. These are compounds containing a 3-hydroxylated cholestane core.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Cholestane steroids
- Direct Parent
- Cholesterols and derivatives
- Alternative Parents
- Delta-5-steroids / Sulfated steroids / Sulfuric acid monoesters / Alkyl sulfates / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aliphatic homopolycyclic compound / Alkyl sulfate / Cholesterol / Delta-5-steroid / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organic sulfuric acid or derivatives / Organooxygen compound / Sulfate-ester
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- steroid sulfate (CHEBI:41321) / Sulfates (LMST05020016)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- KU576NT9O9
- CAS number
- 1256-86-6
- InChI Key
- BHYOQNUELFTYRT-DPAQBDIFSA-N
- InChI
- InChI=1S/C27H46O4S/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(31-32(28,29)30)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25H,6-8,10-17H2,1-5H3,(H,28,29,30)/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
- IUPAC Name
- [(1R,3aS,3bS,7S,9aR,9bS,11aR)-9a,11a-dimethyl-1-[(2R)-6-methylheptan-2-yl]-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid
- SMILES
- [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)OS(O)(=O)=O)[C@H](C)CCCC(C)C
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000653
- KEGG Compound
- C18043
- PubChem Compound
- 65076
- PubChem Substance
- 46507419
- ChemSpider
- 58586
- ChEBI
- 41321
- ChEMBL
- CHEMBL1231592
- ZINC
- ZINC000012494196
- PDBe Ligand
- C3S
- Wikipedia
- Cholesterol_sulfate
- PDB Entries
- 1s0x / 2hka / 2mzi / 2q9f / 4tri / 5kwy / 5nti / 7fjf
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 7.48e-05 mg/mL ALOGPS logP 3.27 ALOGPS logP 7.17 Chemaxon logS -6.8 ALOGPS pKa (Strongest Acidic) -1.4 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 63.6 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 130.61 m3·mol-1 Chemaxon Polarizability 56.55 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9913 Blood Brain Barrier + 0.9462 Caco-2 permeable - 0.6358 P-glycoprotein substrate Substrate 0.5 P-glycoprotein inhibitor I Inhibitor 0.7362 P-glycoprotein inhibitor II Non-inhibitor 0.7758 Renal organic cation transporter Non-inhibitor 0.8077 CYP450 2C9 substrate Non-substrate 0.8231 CYP450 2D6 substrate Non-substrate 0.8288 CYP450 3A4 substrate Substrate 0.7015 CYP450 1A2 substrate Non-inhibitor 0.8072 CYP450 2C9 inhibitor Non-inhibitor 0.8089 CYP450 2D6 inhibitor Non-inhibitor 0.8779 CYP450 2C19 inhibitor Non-inhibitor 0.7464 CYP450 3A4 inhibitor Non-inhibitor 0.884 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5501 Ames test Non AMES toxic 0.548 Carcinogenicity Non-carcinogens 0.5486 Biodegradation Not ready biodegradable 0.9838 Rat acute toxicity 2.4505 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.7589 hERG inhibition (predictor II) Non-inhibitor 0.5388
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 232.6348203 predictedDarkChem Lite v0.1.0 [M-H]- 229.0146178 predictedDarkChem Standard v0.1.0 [M-H]- 239.5586203 predictedDarkChem Lite v0.1.0 [M-H]- 228.65628 predictedDeepCCS 1.0 (2019) [M+H]+ 230.55168 predictedDeepCCS 1.0 (2019) [M+Na]+ 236.67984 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsNuclear receptor ROR-alpha
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of embryonic ...
- Gene Name
- RORA
- Uniprot ID
- P35398
- Uniprot Name
- Nuclear receptor ROR-alpha
- Molecular Weight
- 58974.35 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52